MiMedx Group, Inc. (MDXG) Stock Forecast
MDXG analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $7.40 average of analyst targets
- Upside to target
- +67.0% from the latest close
- Next earnings
- October 28, 2026
- 52-week range
- $3.09 – $7.96
MDXG analyst ratings
5 analystsNumber of analysts at each rating.
MDXG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MDXG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.02 | $0.03 | $0.15 | −100.0% | 3 |
| Current fiscal year (2026) | −$0.08 | −$0.10 | −$0.03 | $0.45 | −117.0% | 3 |
| Next fiscal year (2027) | $0.14 | $0.04 | $0.20 | −$0.08 | +278.3% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MDXG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $68.7M | $65.9M | $71.4M | −39.6% | 5 |
| Current fiscal year (2026) | $267.0M | $261.0M | $272.1M | −36.2% | 5 |
| Next fiscal year (2027) | $323.5M | $291.0M | $416.6M | +21.1% | 5 |
MDXG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MDXG revenue: reported and forecast
MDXG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.00 | $0.01 | $0.01 | $0.01 | $0.00 | −100.0% | 0 up · 2 down |
| Current fiscal year (2026) | −$0.07 | −$0.05 | −$0.06 | −$0.06 | −$0.08 | +9.6% | 0 up · 1 down |
| Next fiscal year (2027) | $0.14 | $0.17 | $0.20 | $0.20 | $0.14 | −4.6% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MDXG earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MDXG beat in 8 of 12.
What analysts expect from MDXG
5 analysts cover MiMedx; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.40, 67.0% above the latest close of $4.43. Analysts expect earnings of −$0.08 per share for 2026, −117.0% from a year earlier. For 2027 the average estimate is $0.14 per share on revenue of $323.5 million. MiMedx beat the EPS estimate in 8 of the last 12 quarters.
Related: MDXG income statement, MDXG key metrics, MDXG chart. See the MDXG stock overview for the latest quote and news.
MDXG forecast FAQ
What is MiMedx's price target?
The average analyst price target for MiMedx is $7.40, 67.0% above the latest close of $4.43.
Is MiMedx a buy, hold or sell?
Of 5 analysts covering MiMedx, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MiMedx's EPS forecast?
Analysts forecast −$0.08 per share for 2026 (range −$0.10 to −$0.03); for 2027 the estimate is $0.14.
What is MiMedx's revenue forecast?
The average revenue estimate for 2026 is $267.0 million, growth of −36.2%; for 2027 it is $323.5 million.
When does MiMedx report earnings?
MiMedx is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes.
Does MiMedx usually beat earnings estimates?
MiMedx reported EPS at or above the analyst estimate in 8 of the last 12 quarters.